As you work tirelessly to change the future of healthcare with cell and gene therapies, Labcorp can support you with the global infrastructure you need combined with the personalized experience you deserve.
4 ways to connect at ASGCT:
1. Stop by booth 1117 and meet with our dedicated cell and gene therapy leaders
2. Don’t miss our scientific symposium on Wednesday, May 8 at 3:45 p.m.
3. Grab a coffee and chat with our scientific team
4. See the latest innovation at one of our featured poster sessions
Scientific symposium
Wednesday, May 8 (3:45 – 4:15 p.m.)
Room 337-338 | Third floor
“To administer or not to administer? The benefits and challenges to the incorporation of immunosuppressive regimens during nonclinical safety evaluations”
Moderated by Brian E. McIntosh, PhD
Director of Science Experts and Global Preclinical Lead of Cell and Gene Therapy, Safety Assessment/Toxicology
The age of advanced therapies has introduced exciting gene therapies to treat, and even cure, debilitating monogenetic diseases. With this introduction, viral systems, such as adeno-associated virus (AAV), have initially emerged as the payload delivery vector of choice. While non-replicating viral capsids have evolved to efficiently infect mammalian cells, human innate and adaptive immune responses to viral proteins remain consistent and pose a potential liability with respect to both safety and efficacy. Treatment with co-immunosuppressive regimens is often sought in the clinic to mitigate immunotoxicity and/or allow the gene therapy to remain active. However, in the evaluation of product safety during the nonclinical phase, a conundrum is continuously at play in relation to the use of immunosuppressives in this setting.
This expert panel will present and discuss a variety of opportunities and challenges associated with the use of immunosuppressive countermeasures during the discovery and/or the nonclinical safety evaluations of viral delivery systems used for gene therapies. Our discussion will provide you with a better understanding of the pros and cons, and how to assess your program considering this insight.
Coffee chats
Plan to join us at booth 1117 during the following times to go deeper into key topics with our knowledgeable on-site team:
Featured poster sessions
Comprehensive AAV characterisation using orthogonal methodologies for empty/full capsid analysis and genome integrity
Session Date/Time: Wednesday, May 8, 12:00 p.m.
Session Title: AAV Vectors - Product Development Manufacturing and Approval Considerations
Session Room: Exhibit Hall
Final Abstract Number: 542
Successful targeted delivery of an AAV reporter via MRI-guided surgery to CNS tissue; feasibility, tolerability, and challenges
Session Date/Time: Thursday, May 9, 12:00 p.m.
Session Title: Neurologic Diseases
Session Room: Exhibit Hall
Final Abstract Number: 1116
Biodistribution of AAV6.2-mCherry in C57BL/6J mouse dosed via nose-only Inhalation route
Session Date/Time: Friday, May 10, 12:00 p.m.
Session Title: AAV Vectors - Preclinical and Proof-of-Concept In Vivo Studies
Session Room: Exhibit Hall
Final Abstract Number: 1491
Rapamycin is an important component of an immunosuppression regimen to inhibit capsid-specific humoral immune responses in high-dose AAV gene therapy in cynomolgus macaques
Session Date/Time: Friday, May 10, 12:00 p.m.
Session Title: AAV Vectors - Immune Modulation
Session Room: Exhibit Hall
Final Abstract Number: 1554